About Mersana
Mersana is a publicly listed company based in Cambridge (United States) founded in 2001, and was acquired by Day One in November 2025. It operates as an antibody-drug conjugates for cancer treatment are developed by Mersana. Mersana has raised $136.23 million across 9 funding rounds from investors including Day One, Takeda Pharmaceuticals and 180 Degree Capital. The company has 102 employees. Mersana offers products and services including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is MERSANA THERAPEUTICS, INC. Its competitors include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma and 2 more; 7 of its 7 listed competitors have raised funding.
Company details
Mersana Therapeutics was founded in 2001 in Cambridge, United States, within the biotechnology sector focused on oncology. Antibody-drug conjugates are developed to target cancer cells precisely. A biodegradable polymer platform called Fleximer is employed to build these immunoconjugates, enabling delivery of anti-tumor agents directly to diseased tissues. Operations center on advancing therapies like the lead candidate XMT-1522, which addresses HER2-positive cancers.
- Headquarters Cambridge, United States
- Employees 102
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website mersana.com
- Social LinkedIn X Facebook
- Acquired by Day One (Nov 2025)
- Legal Name Mersana Therapeutics, Inc.
- Annual Revenue$40.5 M (USD)9.88as on Dec 31, 2024
- Net Profit-$69.19 M (USD)59.69as on Dec 31, 2024
- EBITDA-$71.71 M (USD)57.68as on Dec 31, 2024
- Total Equity Funding$136.23M (USD)
in 9 rounds
- Latest Funding Round$33.1M (USD), Series C
Jun 2016
- InvestorsDay One
& 11 more
- Employee Count102
- Acquired byDay One
(Nov 2025)
Products & Services of Mersana
Mersana offers a comprehensive portfolio of products and services, including Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056.
Platform for developing cytotoxic antibody-drug conjugates for cancer.
Platform for creating immunostimulatory antibody-drug conjugates targeting cancer.
Antibody-drug conjugate in development for cancer treatment applications.
Experimental ADC aimed at improving cancer therapy outcomes.
Funding Insights of Mersana
Mersana has successfully raised a total of $136.23M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $33.1 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $136.23M
- Total Rounds 9
- Last Round Series C — $33.1M
- First Round $4M
(Aug 2008)
- Investors Count 11
All 9 funding rounds of Mersana with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $33.1M | Series C | – | Wellington | |
| Mar 2016 | $10.13M | Series B | – | – | – |
| Mar 2015 | $35M | Series B | – | New Enterprise Associates | |
| Apr 2014 | $14.51M | Series A | – | New Enterprise Associates | – |
| Aug 2012 | $12.5M | Series A | – | – | – |
| Jul 2012 | $27M | Series A | – | New Enterprise Associates | |
| Apr 2012 | $10M | Debt – Conventional | – | – | – |
| Feb 2010 | $2.5M | Debt – Conventional | – | – | – |
| Aug 2008 | $4M | Seed | – | – | – |
12 investors in total: 11 institutional and 1 angel.
Investors in Mersana
Mersana has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Day One, Takeda Pharmaceuticals and 180 Degree Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Venture capital is focused on healthcare by Pfizer's investment arm. | – | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | |
- | – | proquestvc.com | - | |
Early-stage tech startups are invested in by Rho Capital Partners. | – | rho.com | New York, United States | |
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
Diversified asset management services are provided to investors. | 2007 | arrowmarkpartners.com | Denver, United States |
Investor details for Mersana
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mersana
59 people are tracked at Mersana (42 in leadership, 10 in board & advisors, 7 in team); the tracked headcount is 102.
| Name | Role | Group |
|---|---|---|
Chuck Miller | Senior Vice President, Regulatory Affairs | Leadership |
Robert Burger | Vice President, Clinical Development | Leadership |
Nora Zizlsperger | Senior Director Clinical Reseach Scientist | Leadership |
Mohan Bala | SVP & Chief Development Officer | Leadership |
Tori Caldwell | Director, Talent Acquisition | Leadership |
Yuanyuan Li | Director | Leadership |
Martin Huber | President & Chief Executive Officer | Leadership |
Katharin Blackerby-Burke | Executive Director, Medical Writing And Regulatory Strategy | Leadership |
Ilia Ichetovkin | Head Of Companion Diagnostics | Leadership |
Chelsea Bradshaw | Senior Director, Biostatistics | Leadership |
Kavita Baba | Senior Director, Business Development | Leadership |
Brian C. Deschuytner | Chief Operating Officer & Chief Financial Officer | Leadership |
Timothy B. Lowinger | Chief Science & Technology Officer | Leadership |
Alejandra Carvajal | Svp, Chief Legal Officer | Leadership |
Adam Poulin-Kerstien | Vice President, Intellectual Property | Leadership |
Bradley J. Sumrow | Executive Medical Director | Leadership |
Sue Monahan | Director Of Quality | Leadership |
Laurie Donovan | Associate Director, Accounting | Leadership |
Jennifer Kinnemeyer | Director, Pharmacovigilance Operations | Leadership |
Michael Massimo | Director Of Financial Planning And Analysis | Leadership |
39 more people are available in the full profile.
Complete people profiles for Mersana
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Mersana
Mersana is a publicly listed company on the NASDAQ with ticker symbol MRSN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Jun 2017
- Listed onNASDAQ: MRSN
- Listed entityMersana Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS59045L2051
- Share price$29.08 (+0.14% on the day) · 2026-01-07
- Market capitalisation$145.4M
- EPS (diluted, trailing year)$-14.08
- Volume (last session)712,460
- Analyst consensusNeutral
Financials of Mersana
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $40.5M | -$69.2M | -$71.7M |
| 2023 | $36.9M | -$171.7M | -$169.4M |
| 2022 | $26.6M | -$204.2M | -$202.8M |
| 2021 | $43,000 | -$170.1M | -$168.0M |
| 2020 | $828,000 | -$88.0M | -$87.1M |
Detailed financial statements for Mersana
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Mersana
5 dated milestones of Mersana across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Mersana is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series C, of $33.1M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Day One.
Competitors of Mersana
Mersana has 7 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Mersana
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mersana
The website of Mersana (mersana.com) receives about 7.8K visits a month and ranks #3,679,105 among all websites worldwide, #4,722 in Biotechnology and Pharmaceuticals.
- Monthly visits7.8K
▲ 39.4% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,679,105
among all websites
- Category rank#4,722
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.5
- Average visit10 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Mersana. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
argen-x.com | argen-x.com | 100% | – | – | – |
| xencor.com | 99% | 22.2K | #2,563,685 | View details | |
biotica.co.uk | biotica.co.uk | 99% | – | – | – |
| adimab.com | 98% | 6K | #3,760,867 | View details | |
| intracellulartherapies.com | 98% | 10.4K | #2,411,888 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Mersana
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Mersana (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mersana
Complete news archive for Mersana
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mersana
Mersana was founded in 2001 and raised its 1st funding round 7 years after it was founded.
Mersana is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Mersana is a funded company, having raised a total of $136.23M across 9 funding rounds to date. The company's 1st funding round was a Seed of $4M, raised on Aug 2008.
Mersana has 102 employees.
Annual revenue of Mersana is $40.5M as on Dec 31, 2024.
Mersana Therapeutics was founded in 2001 in Cambridge, United States, within the biotechnology sector focused on oncology. Antibody-drug conjugates are developed to target cancer cells precisely. A biodegradable polymer platform called Fleximer is employed to build these immunoconjugates, enabling delivery of anti-tumor agents directly to diseased tissues. Operations center on advancing therapies like the lead candidate XMT-1522, which addresses HER2-positive cancers.
Mersana's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Mersana offers Dolasynthen Platform, Immunosynthen Platform, Emi-Le, and XMT-2056.
Yes, Mersana is publicly traded on NASDAQ under the ticker symbol MRSN.
Mersana has 12 investors. Key investors include Day One, Takeda Pharmaceuticals, 180 Degree Capital, ArrowMark Partners, and NEA.
Mersana operates through Mersana Therapeutics, Inc..
Yes. Mersana was acquired by Day One in November 2025.